🔗 Share this article

Given that the United States proceeds with historic revisions to its vaccine guidelines, one figure appears somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by questioning COVID-19 vaccines in the global health crisis and has focused upon potential deaths after COVID-19 vaccination in her recent position at the FDA.

Proposed Shifts to Pediatric Vaccine Program

Agency leaders were set to announce sweeping revisions to the childhood vaccine schedule recently, synchronizing the US with the Danish immunization schedule, it is understood – a major change that would place the US out of step with much of the world with no evidence for benefit. The announcement has been delayed until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to speak at the event. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the center this calendar year.

A New Direction at the Regulatory Body

This interim role could signify a tighter collaboration between the drug and biologics centers as Dr. Høeg and Prasad consolidate power at the FDA – and it points to a increased emphasis upon dismantling already-approved immunizations at the FDA.

The new acting director has often pushed for ending certain pediatric shot schedules in the US so as to align more similar to Denmark, a society with nationalized medicine and a citizenry approximately the size of the state of Wisconsin.

To date comments, she has continued to focus on immunizations – traditionally the purview of Prasad, head of the FDA’s CBER – as opposed to medication approval.

Doubts Over Background

Dr. Høeg has no apparent background in drug development, oversight or management, which has been typical for former directors of the biologics center. She has worked at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“It seems she lacks to have the requisite experience” for running the drug-regulation department, remarked Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a major agency. She is not an expert in drug approvals.”

Past directors of CBER would “be deeply familiar with legal statutes and the science of drug development”, said a former acting FDA commissioner. “Frankly, she lacks the type of experience that former directors who ran CBER have had.”

This division has an vast range of responsibilities at the FDA, she emphasized.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office approves a multitude of off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and so forth, and every single one must be managed,” Woodcock noted. “The responsibility you overlook, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a substantial management aspect to the role, which manages in excess of 5,000 employees. “It’s a huge administrative position, if you execute it properly,” the former official added.

Agency Reaction and Contentious Policies

Regarding concerns about Høeg’s fitness for the role and whether this assignment represents greater collaboration among agency officials on immunizations, a spokesperson responded that the “questions are based on incorrect premises”.

“Her resume aligns with the functions of her job,” the spokesperson stated, pointing to the period Høeg spent guiding the agency head on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg takes over the commissioner’s controversial priority voucher program, a disputed rapid therapy clearance system that allegedly concerned her predecessors. “How are these therapies being picked for this voucher program? Who makes the calls?” Dr. Howard asked. “There is a lot of confidentiality occurring at the FDA right now.”

Broadly speaking, he stated, “the agency looks to be trending towards less stringent regulations of most medications, with the exception of immunizations.”

Documented Past Work on Immunizations

Regarding immunizations, Høeg has a more established, if problematic, track record, critics have noted. She published a analysis using non-validated crowd-sourced reports to assess the rate of myocarditis after Covid immunization. She counseled the state of Florida chief medical officer Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccines are pose a greater threat than they are.

Included in her “policy goals” for the incoming federal leadership included altering rules for new vaccines and halting “non-essential” vaccines, she stated post-election on a online show. At the agency, Høeg has reportedly suggested preventing teenage boys from receiving Covid vaccines.

“She’s an all-around dogmatist who commences with her beliefs and works backwards to accommodate the evidence in a extremely disingenuous, untruthful fashion,” Howard said.

Gaining Influence and a “Push for Payback”

Høeg joined other dissenters, {like|